These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8068855)

  • 1. Comment on: on the design and analysis of randomized clinical trials with multiple endpoints.
    Lehmacher W; Wassmer G; Reitmeir P
    Biometrics; 1994 Jun; 50(2):581-3. PubMed ID: 8068855
    [No Abstract]   [Full Text] [Related]  

  • 2. On the design and analysis of randomized clinical trials with multiple endpoints.
    Tang DI; Geller NL; Pocock SJ
    Biometrics; 1993 Mar; 49(1):23-30. PubMed ID: 8513104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regarding paper "Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance" by Lui K. J. and Chang K. C.
    Vach W
    Biom J; 2007 Aug; 49(4):627-9; author reply 630-1. PubMed ID: 17722194
    [No Abstract]   [Full Text] [Related]  

  • 4. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratified and randomized play-the-winner rule.
    Liang Y; Carriere KC
    Stat Methods Med Res; 2008 Dec; 17(6):581-93. PubMed ID: 18375460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explanatory analyses of randomized studies.
    Tritchler D
    Biometrics; 1996 Dec; 52(4):1450-6. PubMed ID: 8962463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference or ratio? A note on two-treatment, four-sequence analysis.
    Hutchinson TP; Cairns D
    Biometrics; 1998 Jun; 54(2):788-9. PubMed ID: 9660634
    [No Abstract]   [Full Text] [Related]  

  • 8. An estimator for treatment comparisons among survivors in randomized trials.
    Hayden D; Pauler DK; Schoenfeld D
    Biometrics; 2005 Mar; 61(1):305-10. PubMed ID: 15737107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Judgement post-stratification for designed experiments.
    Du J; MacEachern SN
    Biometrics; 2008 Jun; 64(2):345-54. PubMed ID: 17888038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-only analysis of treatment-covariate interactions in clinical trials.
    Vittinghoff E; Bauer DC
    Biometrics; 2006 Sep; 62(3):769-76. PubMed ID: 16984319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of two-stage test statistic in the two-period crossover trials.
    Wang SJ; Hung HM
    Biometrics; 1997 Sep; 53(3):1081-91. PubMed ID: 9333341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatekeeping testing via adaptive alpha allocation.
    Li JD; Mehrotra DV
    Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
    Eickhoff JC
    Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
    Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
    Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial by Christopher J. Weir and Kennedy R. Lees, Statistics in Medicine 2003; 22:705-726.
    McEntegart DJ
    Stat Med; 2004 Dec; 23(23):3719-20; author reply 3720-1. PubMed ID: 15534886
    [No Abstract]   [Full Text] [Related]  

  • 16. [Methodological aspects of biostatistics and epidemiology in a clinical trial].
    Suárez E; Pérez CM
    P R Health Sci J; 1999 Mar; 18(1):23-30. PubMed ID: 10343983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intent-to-treat analysis for longitudinal studies with drop-outs.
    Little R; Yau L
    Biometrics; 1996 Dec; 52(4):1324-33. PubMed ID: 8962456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of two methods for adaptive interim analyses in clinical trials.
    Wassmer G
    Biometrics; 1998 Jun; 54(2):696-705. PubMed ID: 9629649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
    Lassere MN
    Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.